|Oncolytics continues to push their pipeline further|
|By Patrick Crutcher|
|Thursday, 02 December 2010 04:15|
Oncolytics Biotech Inc.(NASDAQ: ONCY) is another company pushing the limits of immunotherapeutics. Yesterday, they announced that enrollment had in a randomized Phase 2 ovarian cancer study using Reolysin. They currently have 11 ongoing studies.
This study will be a randomized phase 2 trial of weekly paclitaxel versus weekly paclitaxel with Reolysin in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). They recently also began a Phase 1 trial in pediatric patients with relapsed or refractory solid tumors and announced some promising publications regarding their lead candidate, Reolysin.
With ONCY conducting eleven(11) clinical trials in the U.K. and U.S., it makes you wonder how they've done it without heavily diluting. This has only been possible thru collaborative agreements with the National Cancer Institute(NCI) in the U.S. to conduct multiple clinical trials, the Cancer Therapy and Research Center at the University of Texas Health Science Center has committed to funding up to five(5) Phase II clinical trials using Reolysin in combination with chemotherapy against a variety of advanced cancers, and sponsored studies in the UK. Oncolytics Biotech and clinical collaborators are actively testing Reolysin in ovarian cancer, colorectal cancer ( only patients with mutated Kras gene), melanoma, sarcoma, and pancreatic cancer.
Financially, these agreements have kept them afloat except for the occasional capital raise. More importantly, they are running a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers that's being conducted under a Special Protocol Assessment(SPA). As we get close to top-line results later on down the road, you can be sure that volatility will increase. The Street and big pharma will be watching.
Disclosure: No position.
Recent ONCY news - http://www.integratir.com/newsrelease.asp?ticker=t.onc
ONCY pipeline - http://www.oncolyticsbiotech.com/clinical.html